



## General description

Daunorubicin is an anthracycline antineoplastic agent that inhibits DNA and RNA synthesis. It is used in treatment protocols for acute lymphoblastic leukaemia, acute myelogenous leukaemia and acute promyelocytic leukaemia.

INN	Daunorubicin
ATC codes	L01DB02
Medicine type	Chemical agent
EML status history	First added in 1999 (TRS 895) for <b>Lymphoid leukaemia, not elsewhere classified</b> Added in 1999 (TRS 895) for <b>Acute myeloid leukaemia with recurrent genetic abnormalities</b> Added in 1999 (TRS 895) for <b>Myeloid leukaemia</b>
Wikipedia	<a href="#">Daunorubicin</a> 
DrugBank	<a href="#">Daunorubicin</a> 

## Recommendations

Section    Cytotoxic medicines

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### Indications

Lymphoid leukaemia, not elsewhere classified

Myeloid leukaemia

Acute myeloid leukaemia with recurrent genetic abnormalities

